Speaking to CNBC-TV18 on the impact of the surprise audit on the company, Sarabjit Kour Nangra, Angel Broking advises investors not to panic and wait till the details of the audit report are released. According to Nangra, Sun's merger with Ranbaxy ... Moneycontrol.com, 1 week ago
'Accumulate' Cipla with target at Rs 480: Angel Broking - Myiris, 1 month ago
Buy Infosys with target price of Rs 4245: Angel Broking - Money Control, 2 months ago
1 images for "sarabjit kour nangra"
HYDERABAD: The National Pharmaceutical Pricing Authority (NPPA) has capped the prices of 43 formulation packs including drugs such as antibiotic Ciprofloxacin, BCG vaccine and anti-diabetic Metformin. The price revision was done as per the Drug ...New Indian Express, 22 hours ago NPPA caps prices of 43 drug formulation packs Business Standard India, 1 day ago 43 more drugs brought under price control Hindu Business Line, 2 days ago
German biopharmaceuticals company Merck Serono has found a partner in Lupin Pharma, where they would together make and market around 20 newer products of core therapeutic areas like diabetes and cardiovascular in emerging economies. The initial ...Financial Chronicle, 3 days ago Angel Broking remains neutral on Cipla and Cadila Healthcare MyIris, 5 days ago Angel Broking remains neutral on Lupin MyIris, 4 days ago Angel Broking remains neutral on Ranbaxy Labs MyIris, 4 days ago
The impact of Taro's recalled products is not much but any adverse regulatory action on the Halol plant will hurt Ujjval Jauhari September 12, 2014 Last Updated at 22:35 IST Sun Pharmaceutical Industries' stock, which lost 4.2 per cent on Thursday ...Business Standard India, 1 week ago
September 12, 2014 By Jessica Wilson , BioSpace.com Breaking News Staff Share prices of Mumbai-based Sun Pharmaceutical Industries continued to drop Friday in the wake of reports that the U.S. Food and Drug Administration (FDA) performed a ...BioSpace, 1 week ago Sun Pharma stock price reacts on news of US FDA's surprise plant inspection The Hindu, 1 week ago
Shares of Sun Pharmaceutical Industries and Ranbaxy Laboratories have dipped up to 4% extending their previous day's fall on reports of drug regulator, US Food and Drug Administration (FDA) conducting a surprise inspection of the Sun Pharma's ...Smart Investor, 1 week ago Sun Pharma, Ranbaxy extend fall on US FDA's surprise plant inspection Smart Investor, 1 week ago
Shares of Sun Pharmaceutical Industries dropped over 4% on Thursday on unconfirmed reports that the US Food and Drug Administration (FDA) made a surprise inspection at its manufacturing facility at Halol in Gujarat. The scrip opened at Rs 853 on ...DNA India, 1 week ago Sun Pharma falls 4% on surprise inspection reports Business Today India, 1 week ago Sun Pharma shares dip on surprise audit by USFDA at Halol plant IndiaVision, 1 week ago Sun Pharma falls 6% as USFDA inspects Halol unit; facility contributes 40% of US sales Economic Times, 1 week ago
More from: , Hindu Business Line...and 3 other sources
(For a Real M&A column news alert: SALT REALMNA .) Sept. 4 (Bloomberg) -- For acquirers willing to look past U.S. punishments for quality and hygiene violations at two plants, Indian drugmaker Wockhardt Ltd. is offering the prospect of a return to ...La Repubblica, 2 weeks ago Wockhardt Comeback Sets Up Drugmaker as Target: Real M Bloomberg, 2 weeks ago
More from: , BusinessWeek...and 1 other sources
Cipla , leading drug maker, announced the launch of Serroflo, its Salmeterol/Fluticasone MDI, in Germany and Sweden. With this launch, Cipla opens the door for new, highly efficient treatments in the European healthcare market. Serroflo will substantially ...Myiris, 2 weeks ago
Value investing must be the most talked about investment philosophy on the planet. One reason for this is that it can deliver good returns in all types of market situations. So, when stock markets are down in the dumps, value investors such as ...Business Today India, 1 month ago
on your WebpageAdd Widget >Get your members hooked!